

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

Moderna Therapeutics, Inc.

Petitioner

v.

Protiva Biotherapeutics, Inc.

Patent Owner

---

U.S. Patent No. 9,364,435

Issued: June 14, 2016

Named Inventor: Edward Yaworski, Kieu Lam,  
Lorne Palmer, Ian MacLachlan

Title: Lipid Formulations for Nucleic Acid Delivery

---

**DECLARATION OF ANDREW S. JANOFF, PH.D.  
IN SUPPORT OF MODERNA THERAPEUTICS, INC.'S  
PETITION FOR *INTER PARTES* REVIEW  
OF U.S. PATENT NO. 9,364,435**

Mail Stop: PATENT BOARD  
Patent Trial and Appeal Board  
U.S. Patent & Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

ARBUTUS - EXHIBIT 2028

Moderna Therapeutics, Inc. v. Arbutus Biopharma Corporation

## TABLE OF CONTENTS

	<u>Page</u>
I. INTRODUCTION.....	1
II. SUMMARY OF OPINIONS.....	1
III. QUALIFICATION AND EXPERIENCE.....	3
IV. LEVEL OF ORDINARY SKILL IN THE ART.....	7
V. LEGAL PRINCIPLES.....	8
A. Claim Construction .....	8
B. Prior Art.....	10
C. Anticipation.....	10
D. Obviousness .....	11
VI. BACKGROUND.....	15
A. Lipid carrier particles for nucleic acid payloads.....	15
B. The '435 patent disclosure .....	21
C. Claim construction .....	28
D. Prior art.....	28
VII. THE CHALLENGED CLAIMS ARE INVALID .....	35
A. Ground 1: Claims 1-20 are obvious in view of the Patent Owner's Prior Disclosures .....	35
B. Ground 2: Claims 1-20 are obvious in view of the '196 PCT in light of Lin and/or Ahmad .....	50
C. Ground 3: Claims 1-20 are anticipated by or obvious in view of the '554 publication .....	53
VIII. CONCLUSION .....	66

I, Dr. Andrew S. Janoff, PhD, declare as follows:

## **I. INTRODUCTION**

1. My name is Andrew S. Janoff. I am a consultant in biotechnology and drug delivery, primarily focusing on lipid and liposome technology.

2. I have been engaged by Moderna Therapeutics, Inc. (“Moderna”) as an expert in connection with matters raised in the Petition for *Inter Partes* Review (“Petition”) of U.S. Patent No. 9,364,435 (the “’435 patent”) owned by Protiva Biotherapeutics, Inc. (“Patent Owner”).

3. This declaration is based on the information currently available to me. To the extent that additional information becomes available, I reserve the right to continue my investigation and study, which may include a review of documents and information that may be produced, as well as testimony from depositions that have not yet been taken.

## **II. SUMMARY OF OPINIONS**

4. The ’435 patent is entitled “Lipid Formulations for Nucleic Acid Delivery.” Ex. 1001. The ’435 patent is directed to a composition of nucleic acid-lipid particles (*e.g.*, particles that can be used to deliver therapeutic nucleic acid payloads to a patient) comprising three lipid components (*i.e.*, cationic lipid, non-cationic lipid and conjugated lipid), each of which fall within a claimed proportion with regard to the total lipid in the particles. *See, e.g., id.*, cl. 1. The Petition challenges claims 1-20 of the ’435 patent.

5. Petitioner's Ground 1 challenges claims 1-20 of the '435 patent as obvious under 35 U.S.C. § 103 in view of Patent Owner's prior disclosures in PCT/CA2004/001051, Publication No. WO2005007196 A2 ("196 PCT"), Ex. 1002, or U.S. Publication No. US2006/0134189 ("189 publication"), Ex. 1003. Based on studying the petition and the exhibits cited in the petition as well as other documents, it is my opinion that claims 1-20 of the '435 patent are obvious in view of the '196 PCT or '189 publication.

6. Petitioner's Ground 2 challenges claims 1-20 of the '435 patent as obvious in view of the Patent Owner's prior disclosures in light of Lin (Ex. 1005) and/or Ahmad (Ex. 1006) under 35 U.S.C. § 103. Based on studying the petition and the exhibits cited in the Petition as well as other documents, it is my opinion that claims 1-20 of the '435 patent are obvious in view of the Patent Owner's prior disclosures in light of Lin and/or Ahmad.

7. Petitioner's Ground 3 challenges claims 1-20 of the '435 patent as anticipated by the disclosures in U.S. Publication No. US2006/0240554 ("554 publication"), Ex. 1004, under pre-AIA 35 U.S.C. § 102(b) or, in the alternative, as obvious under 35 U.S.C. § 103 in view of the '554 publication. Based on studying the petition and the exhibits cited in the petition as well as other documents, it is my opinion that claims 1-20 of the '435 patent are anticipated by the '554 publication. In the alternative, it is my opinion that claims 1-20 of the '435 patent are obvious in view of the '554 publication.

### III. QUALIFICATION AND EXPERIENCE

8. I am formally trained as a membrane biophysicist. I obtained my Ph.D. degree in Biophysics from Michigan State University in 1980. Before that, I received my MS in Biophysics from Michigan State University in 1977, and my BS in Biology from The American University in 1971. I received postdoctoral training in Pharmacology at the Harvard Medical School and in Anesthesia at the Massachusetts General Hospital.

9. I have played leadership roles in the discipline of pharmaceutical liposomology from its inception in 1981.

10. After my post-doctoral work, I was recruited from Harvard by the industrialist, Jack Whitehead, and became the first senior founding scientist at the Liposome Company, Inc. I eventually became the Vice President of Research and Development at the Liposome Company. I led the team at the Liposome Company that discovered, formulated, and developed ABELCET, a novel lipid structure that is approved worldwide for systemic fungal infections. I first published the physical chemical characterization of this structure, along with an explanation of why it would yield a less toxic alternative to the traditional micelle formulation in the *Proceedings of the National Academy of Sciences*.

11. I led the team at the Liposome Company that developed Staclot LA, a diagnostic reagent comprised of Hexagonal (II) lipid that is a standard

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.